RecruitingPhase 2NCT07598396

A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

A Phase II Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Mosunetuzumab in Patients With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

Sponsor

Hoffmann-La Roche

Enrollment

30 participants

Start Date

May 25, 2026

Study Type

INTERVENTIONAL

Conditions

Systemic Lupus Erythematosus Lupus Lupus Nephritis

Summary

This study will assess how mosunetuzumab works in people who have systemic lupus erythematosus (SLE) who may or may not also have active lupus nephritis (LN).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Mosunetuzumab for people with lupus, lupus nephritis, and other related conditions. The study is currently recruiting participants at 15 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMosunetuzumab

Participants will receive SC mosunetuzumab.

Locations(15)

Clnica SER da Bahia

Salvador, Estado de Bahia, Brazil

L2IP ?Instituto de Pesquisas Clínicas Ltda.

Brasília, Federal District, Brazil

IPC MT Instituto de Pesquisas Clinicas do Mato Grosso

Cuiab, Mato Grosso, Brazil

Complexo Hospitalar de Niteroi

Niterói, Rio de Janeiro, Brazil

LMK Servios Mdicos S/S Ltda

Porto Alegre, Rio Grande do Sul, Brazil

Hospital das Clinicas de Ribeirao Preto

Ribeiro Preto, São Paulo, Brazil

Hospital das Clnicas da Faculdade de Medicina da USP

São Paulo, São Paulo, Brazil

Clinica de la Costa S.A.S

Barranquilla, Colombia

Centro de Investigacion en Reumatologia y Especialdades Medicas SAS. CIREEM

Bogotá, Colombia

Hospital Pablo Tobon Uribe

Medellín, Colombia

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Rome, Lazio, Italy

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili)

Brescia, Lombardy, Italy

Emmed Research

Pretoria, Gauteng, South Africa

University of Cape Town Kidney and Hypertension Research Unit

Cape Town, Western Cape, South Africa

Clinical Trials Network Helderberg

Somerset West, Western Cape, South Africa

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07598396

Related Trials

Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions

NCT048334651 location

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

NCT072629831 location

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT06617325233 locations

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

NCT07409181138 locations

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

NCT0657079857 locations